Woods Keith W, Fischer John P, Claiborne Akiyo, Li Tongmei, Thomas Sheela A, Zhu Gui-Dong, Diebold Robert B, Liu Xuesong, Shi Yan, Klinghofer Vered, Han Edward K, Guan Ran, Magnone Shayna R, Johnson Eric F, Bouska Jennifer J, Olson Amanda M, de Jong Ron, Oltersdorf Tilman, Luo Yan, Rosenberg Saul H, Giranda Vincent L, Li Qun
Cancer Research, Department R47S, AP10, Abbott Laboratories, Abbott Park, IL 60064, USA.
Bioorg Med Chem. 2006 Oct 15;14(20):6832-46. doi: 10.1016/j.bmc.2006.06.047. Epub 2006 Jul 14.
A series of heteroaryl-pyridine containing inhibitors of Akt are reported. The synthesis and structure-activity relationships are discussed, leading to the discovery of a indazole-pyridine analogue (K(i)=0.16 nM). These compounds bind in the ATP binding site, are potent, ATP competitive, and reversible inhibitors of Akt activity. No selectivity amongst the Akt isoforms is observed for this analogue, but there is good selectivity against an panel of other kinases. It is least selective for other members of the AGC family of kinases but is nonetheless 40-fold selective for Akt over PKA. The compound shows cellular activity and significantly slows tumor growth in vivo.
报道了一系列含杂芳基吡啶的Akt抑制剂。讨论了其合成及构效关系,从而发现了一种吲唑吡啶类似物(抑制常数K(i)=0.16 nM)。这些化合物结合于ATP结合位点,是强效的、ATP竞争性且可逆的Akt活性抑制剂。对于该类似物,未观察到Akt亚型之间的选择性,但对一组其他激酶具有良好的选择性。它对AGC激酶家族的其他成员选择性最低,但对Akt的选择性仍比对蛋白激酶A(PKA)高40倍。该化合物显示出细胞活性,并在体内显著减缓肿瘤生长。